Individualised Treatment Targets for Elderly Patients With Type 2 Diabetes Using Vildagliptin Add-on or Lone Therapy (INTERVAL): A 24 Week, Randomised, Double-Blind, Placebo-Controlled Study

Study Questions:

What is the feasibility of setting and achieving individualized targets over 24 weeks, along with conventional glycosylated hemoglobin (HbA1c) reduction, using vildagliptin compared to placebo?